By failing to integrate AI into the SAT, the College Board is hitting ignoring the digital revolution that has already reshaped classrooms.

A simple prompt pulls up an interface that resembles an online test environment. You get explanations for wrong answers and detailed feedback at the end.

Did Stephen Colbert "reveal" Donald Trump's "1970 Wharton IQ test"? No, that's not true: This claim and its variations ...

NEXT is preparing to release its fourth quarter (Q4) 2025 sales and revenue figures, a key milestone in the group's financial calendar that will shed light on how the retailer's performance has ...

Housing inventory fell 5.9% in November from October. The median price of a home sold in November, meanwhile, was $409,200, an increase of 1.2% from November 2024. Homes are staying on the market ...

Electric vehicle sales experienced a significant 61% drop, while F-Series pickup sales also fell nearly 10%. Despite the overall dip, sales for the Explorer SUV, Maverick pickup and Ranger pickup saw ...

Miami fairgoers have long had to ping-pong between NADA and Untitled Art, making strategic decisions about which fair to hit first to game the traffic and catch the best discoveries before they ...

WASHINGTON (AP) — Sales at U.S. retailers and restaurants increased modestly in September as resilient consumers moderated their spending after splurging over the summer. Sales rose 0.2% in September ...

Tesla could see its first full-year sales decline in China this year. The electric vehicle maker's sales in China dropped to a three-year low in October. The U.S. automaker's Chinese EV market share ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Smith confirmed, "Looking at Q4, we expect AI-related demand for compute, networking and memory to be the primary engine of our growth." Mehta guided, "Q4 sales are expected to be between $920 million ...

NEW YORK – Visby Medical has informed its clinical customers that it will soon stop providing molecular diagnostic tests for the point-of-care CLIA-waived market and instead shift its resources to ...